Could a Type 2 Diabetes Drug Tackle Kidney Stones?
An analysis of pooled data from phase 1-4 clinical trials of empagliflozin for blood glucose control in 15,081 patients with type 2 diabetes found patients with type 2 diabetes who received empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, were almost 40% less likely to have a kidney stone than patients who received placebo during a median 1.5 years of treatment.

Source: https://www.medscape.com/viewarticle/975884?src=rss#vp_1
Like
Comment
Share